Addressing Unmet Needs with [18F]FAPI-74

Presented by: Sherly Mosessian, PhD, Chief Scientific Officer, SOFIE
8th Theranostics World Congress; Cape Town, South […]

2026-02-04T01:17:40+00:004, Feb 2026|Presentations|

SOFIE drives U.S. manufacture of [18F]FAPI-74

Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials […]

2026-01-27T14:57:34+00:0027, Jan 2026|News|

SOFIE’s Phase 2 FAPI Study Outcomes Showcased at ASCO GI 2026

Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological […]

2026-01-23T00:27:04+00:0023, Jan 2026|News|

SOFIE activates FAPI-PRO, second [18F]FAPI-74 Phase 3 trial

FAPI-PRO is a GO!

SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]

2025-12-12T18:06:28+00:0012, Dec 2025|News|

Focus on FAPI Newsletter – Q4 2025

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI […]

2025-12-03T20:11:28+00:002, Dec 2025|Newsletter|

SOFIE activates FAPI-GO, first [18F]FAPI-74 Phase 3 trial

Another defining moment for SOFIE Biosciences!

Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 […]

2025-11-17T16:54:53+00:0017, Nov 2025|News|

Mosessian Named one of Top 25 Women Chief Scientific Officers in 2025

Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the […]

2025-10-24T16:14:21+00:0024, Oct 2025|News|

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients

Adrien Holzgreve, Lena M Unterrainer, Kimberly Flores, Ethan C Lam, Christine E Mona, Johannes Czernin, […]

2025-12-02T18:50:00+00:0016, Oct 2025|Publications|
Go to Top